Back to top
more

PHASEBIO PHARMA (PHAS)

(Delayed Data from NSDQ)

$13.25 USD

13.25
111,216

-0.13 (-0.97%)

Updated May 3, 2019 04:00 PM ET

After-Market: $13.24 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

PhaseBio Pharmaceuticals (PHAS) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

PhaseBio Pharmaceuticals (PHAS) delivered earnings and revenue surprises of -3.03% and 91.68%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ITeos Therapeutics, Inc. (ITOS) Q2 Earnings and Revenues Lag Estimates

by Zacks Equity Research

iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of -87.50% and 56.97%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

UniQure (QURE) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

uniQure (QURE) delivered earnings and revenue surprises of 12.50% and 97.47%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

PhaseBio Pharmaceuticals (PHAS) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

PhaseBio Pharmaceuticals (PHAS) delivered earnings and revenue surprises of 65.67% and 98%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

PhaseBio (PHAS) Dips on Mixed Data From Antiplatelet Drug Study

by Zacks Equity Research

PhaseBio's (PHAS) phase III study evaluating bentracimab for the reversal of antiplatelet effects of ticagrelor meets primary endpoint. The stock falls on high rates of the drug's side effects.

PhaseBio Pharmaceuticals (PHAS) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

PhaseBio Pharmaceuticals (PHAS) delivered earnings and revenue surprises of -6.45% and -87.43%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Do Options Traders Know Something About PhaseBio Pharmaceuticals (PHAS) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to for PhaseBio Pharmaceuticals (PHAS) stock based on the movements in the options market lately.

New Strong Sell Stocks for August 3rd

by Zacks Equity Research

CAE, DRQ, FRPT, ORC and PHAS have been added to the Zacks Rank #5 (Strong Sell) List on August 3, 2021.

PHASEBIO PHARMA (PHAS) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

PHASEBIO PHARMA (PHAS) delivered earnings and revenue surprises of -31.82% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate PHASEBIO PHARMA (PHAS) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

PHASEBIO PHARMA (PHAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is the Options Market Predicting a Spike in PhaseBio (PHAS) Stock?

by Zacks Equity Research

Investors need to pay close attention to PhaseBio (PHAS) stock based on the movements in the options market lately.

PHASEBIO PHARMA (PHAS) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

PHASEBIO PHARMA (PHAS) delivered earnings and revenue surprises of -96.00% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate PHASEBIO PHARMA (PHAS) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

PHASEBIO PHARMA (PHAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PhaseBio Initiates Phase II Study for Coronavirus Patients

by Zacks Equity Research

PhaseBio (PHAS) initiates phase II study of PB1046 in hospitalized COVID-19 patients at high risk for rapid clinical deterioration and acute respiratory distress syndrome.

Biotech Stock Roundup: GILD's Coronavirus Drug Update, NTLA-REGN Deal & More

by Zacks Equity Research

The biotech sector remains in focus with updates on coronavirus treatments and presentations at ASCO.

Zacks.com headshot

PhaseBio Gets FDA Nod to Begin Study for Coronavirus Treatment

by Zacks.com

PhaseBio (PHAS) receives clearance of IND application from the FDA to evaluate PB1046 as a treatment for hospitalized COVID-19 patients.

PHASEBIO PHARMA (PHAS) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

PHASEBIO PHARMA (PHAS) delivered earnings and revenue surprises of -26.83% and -14.67%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate PHASEBIO PHARMA (PHAS) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

PHASEBIO PHARMA (PHAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PhaseBio Pharmaceuticals, Inc. (PHAS) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in PhaseBio Pharmaceuticals, Inc. (PHAS).

Analysts Estimate PHASEBIO PHARMA (PHAS) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

PHASEBIO PHARMA (PHAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PHASEBIO PHARMA (PHAS) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

PHASEBIO PHARMA (PHAS) delivered earnings and revenue surprises of -11.11% and -31.34%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

PhaseBio Stock Up on Breakthrough Therapy Status for PB2452

by Zacks Equity Research

FDA grants PhaseBio's (PHAS) lead pipeline candidate, PB2452, Breakthrough Therapy status for treating bleeding risk associated with, AstraZeneca's antiplatelet drug Brilinta.

PhaseBio Stock Up on Positive Data From PB2452 Phase I Study

by Zacks Equity Research

PhaseBio's (PHAS) stock skyrockets on positive data from an early-stage study evaluating PB2452, showing immediate and sustained reduction in bleeding risk in patients taking AstraZeneca's Brilinta.